The clinical entities of IPEX and APS1 caused by the mutations of FOXP3 and AIRE, respectively, are likely to be the first of a string of new primary monogenic diseases that can be used for discovery of immune regulatory mechanisms and targeted interventions. Here, FOXP3 is linked to immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome.